Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 10/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 5/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30422661 | 0.91 | MAPT (0.42) | MAPTPTPN11POLBPDE5A | |
| SCHEMBL25244064 | 0.91 | MAPT (0.42) | MAPTPTPN11POLBPDE5A | |
| SCHEMBL30422804 | 0.90 | MAPT (0.46) | MAPTPTPN11POLB | |
| Hydrochloric Acid SCHEMBL30422691 | 0.90 | MAPT (0.45) | MAPTPTPN11POLB | |
| Hydrochloric Acid SCHEMBL25421643 | 0.90 | MAPT (0.45) | MAPTPTPN11POLB | |
| SCHEMBL30422856 | 0.86 | MAPT (0.45) | MAPTPTPN11POLB | |
| SCHEMBL25418681 | 0.86 | MAPT (0.45) | MAPTPTPN11POLB | |
| Hydrochloric Acid SCHEMBL30422569 | 0.86 | MAPT (0.45) | MAPTPTPN11POLB | |
| SCHEMBL24032841 | 0.84 | DYRK1A (0.40) | MAPTPTPN11LRRK2 | |
| Trifluoroacetic Acid SCHEMBL30423010 | 0.84 | MAPT (0.38) | MAPTPTPN11POLBPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122192-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| EP-4441042-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | Rgenta Therapeutics, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-118748995-A | 5-Pyrimidine carboxamide derivatives and methods of use thereof | 亚根达医疗公司 | 2024-10-08 | — | — | CN | disclosed |
| WO-2023102231-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122192-A1 | 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME | RTCB, NSUN2, PRPF19 | MAPT 4668/4885PTPN11 4344/4885POLB 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.